You are here: Industry Insights > Lilly

News List

Aleor Dermaceuticals gets USFDA nod for Testosterone Topical Solution expresspharma
June 18, 2021
It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism and Hypogonadotropic hypoqonadisrn.
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous No prnasia
June 04, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company jointly ...
Lilly India gets nod for restricted EU of monoclonal antibody drugs, bamlanivimab and etesevimab to treat COVID-19 expresspharma
June 02, 2021
Bamlanivimab and etesevimab together have been authorised under Emergency Use Authorization in the US and select EU countries, for the treatment of mild to moderate COVID-19.
US DOJ probes Eli Lilly’s Branchburg manufacturing site pharmaceutical-technology
May 31, 2021
The US Department of Justice (DOJ) has issued a subpoena to Eli Lilly seeking some documents related to its manufacturing facility in Branchburg, New Jersey, US.
Eli Lilly and MiNA Therapeutics enter saRNA-based drug research deal pharmaceutical-technology
May 26, 2021
RNA therapy, which selectively activates a specific gene in a patient’s cells, has the potential to treat a wide range of diseases, including cancer.
Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine pharmatimes
May 25, 2021
Eli Lilly’s investigational candidate tirzepatide achieved superior A1C and body weight reductions compared with insulin glargine in adults with type 2 diabetes who have increased cardiovascular risk.
Arecor, Lilly Signs Formulation Study Partnership contractpharma
May 21, 2021
Arecor will use its proprietary formulation technology platform to develop a differentiated, thermostable formulation of one of Lilly’s proprietary products.
BDR Pharma signs voluntary licensing agreement with Lilly for baricitinib expresspharma
May 20, 2021
Lilly had recently announced seven other voluntary license agreements with major drug manufacturers in India for the production of baricitinib.
U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer prnasia
May 18, 2021
Innovent Biologics, Inc. and Eli Lilly and Company today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in combination with pemetrexed and platinum ...
Lilly signs voluntary licensing agreement with Natco for baricitinib expresspharma
May 18, 2021
Lilly had also signed voluntary license agreements with Cipla, Lupin, Sun Pharma, Dr Reddy’s, MSN Labs and Torrent Pharma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page